Antimicrobial Resistance Profile of MDR & Non-MDR Meropenem-Resistant Pseudomonas aeruginosa Isolates of Patients in Intensive Care Unit of Tertiary Hospital

Imaculata Sonia Vidaryo Lameng, Ni Nyoman Sri Budayanti, Luh Inta Prilandari, I. K. A. I. Adhiputra
{"title":"Antimicrobial Resistance Profile of MDR & Non-MDR Meropenem-Resistant Pseudomonas aeruginosa Isolates of Patients in Intensive Care Unit of Tertiary Hospital","authors":"Imaculata Sonia Vidaryo Lameng, Ni Nyoman Sri Budayanti, Luh Inta Prilandari, I. K. A. I. Adhiputra","doi":"10.20473/ijtid.v9i3.30000","DOIUrl":null,"url":null,"abstract":"Pseudomonas aeruginosa is one of the gram-negative bacteria that causes infection in the Intensive Care Unit (ICU) which is easily resistant. Patients infected with carbapenem-resistant P. aeruginosa are predicted to have a poor prognosis. This study aims to know the resistance profile of meropenem-resistant P. aeruginosa in the ICU. The results of this study can be used as a measure on the success of antimicrobial resistance control, infection control programs and become a reference for empirical therapy in the ICU. This study used a cross-sectional retrospective descriptive research method and was carried out at the Clinical Microbiology Laboratory of Sanglah Hospital Denpasar for three years, from 2018 to 2020. The results showed 38 of the 93 isolates of P. aeruginosa in the ICU were resistant to meropenem and were derived from sputum and urine. The percentage of meropenem-resistant P. aeruginosa isolates was higher in the multi-drug-resistant group and mostly came from sputum specimens. In 2018, Non-MDR meropenem-resistant P. aeruginosa isolates was that 100% sensitive to all other antibiotics used to treat P. aeruginosa infections, including; ceftazidime, cefepime, ciprofloxacin, gentamicin, amikacin, and piperacillin-tazobactam. In 2019 no meropenem-resistant P. aeruginosa isolates were found. In 2020, its sensitivity to antibiotics ceftazidime and piperacillin-tazobactam was 20.0%, ciprofloxacin 60.0% and to antibiotics gentamicin and amikacin 100%. MDR meropenem-resistant P. aeruginosa isolates in 2018 were still sensitive to ceftazidime (15.4%) and amikacin (69.2%) antibiotics, while in 2019 they were only sensitive to amikacin (37.5%). In 2020, P. aeruginosa isolates were sensitive to the antibiotics ceftazidime and cefepime (11.1%), piperacillin-tazobactam (22.2%), and amikacin (88.9%). Amikacin may be the choice of treatment for MDR meropenem-resistant P. aeruginosa.","PeriodicalId":13538,"journal":{"name":"Indonesian Journal of Tropical and Infectious Disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indonesian Journal of Tropical and Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20473/ijtid.v9i3.30000","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Pseudomonas aeruginosa is one of the gram-negative bacteria that causes infection in the Intensive Care Unit (ICU) which is easily resistant. Patients infected with carbapenem-resistant P. aeruginosa are predicted to have a poor prognosis. This study aims to know the resistance profile of meropenem-resistant P. aeruginosa in the ICU. The results of this study can be used as a measure on the success of antimicrobial resistance control, infection control programs and become a reference for empirical therapy in the ICU. This study used a cross-sectional retrospective descriptive research method and was carried out at the Clinical Microbiology Laboratory of Sanglah Hospital Denpasar for three years, from 2018 to 2020. The results showed 38 of the 93 isolates of P. aeruginosa in the ICU were resistant to meropenem and were derived from sputum and urine. The percentage of meropenem-resistant P. aeruginosa isolates was higher in the multi-drug-resistant group and mostly came from sputum specimens. In 2018, Non-MDR meropenem-resistant P. aeruginosa isolates was that 100% sensitive to all other antibiotics used to treat P. aeruginosa infections, including; ceftazidime, cefepime, ciprofloxacin, gentamicin, amikacin, and piperacillin-tazobactam. In 2019 no meropenem-resistant P. aeruginosa isolates were found. In 2020, its sensitivity to antibiotics ceftazidime and piperacillin-tazobactam was 20.0%, ciprofloxacin 60.0% and to antibiotics gentamicin and amikacin 100%. MDR meropenem-resistant P. aeruginosa isolates in 2018 were still sensitive to ceftazidime (15.4%) and amikacin (69.2%) antibiotics, while in 2019 they were only sensitive to amikacin (37.5%). In 2020, P. aeruginosa isolates were sensitive to the antibiotics ceftazidime and cefepime (11.1%), piperacillin-tazobactam (22.2%), and amikacin (88.9%). Amikacin may be the choice of treatment for MDR meropenem-resistant P. aeruginosa.
三级医院重症监护病房患者耐多药和非耐多药美罗培南铜绿假单胞菌耐药性分析
铜绿假单胞菌是导致重症监护室(ICU)感染的革兰氏阴性菌之一,很容易产生耐药性。预计感染碳青霉烯耐药性铜绿假单胞菌的患者预后较差。本研究旨在了解ICU中耐美罗培南铜绿假单胞菌的耐药性。本研究的结果可作为衡量抗菌药物耐药性控制、感染控制计划成功与否的指标,并可作为ICU经验治疗的参考。这项研究采用了横断面回顾性描述性研究方法,于2018年至2020年在登巴萨桑拉医院临床微生物实验室进行了三年。结果显示,ICU中93株铜绿假单胞菌中有38株对美罗培南具有耐药性,来源于痰液和尿液。耐美罗培南的铜绿假单胞菌在耐多药组中的比例较高,且大多来自痰标本。2018年,非耐多药美罗培南耐药性铜绿假单胞菌分离株对用于治疗铜绿假单胞杆菌感染的所有其他抗生素100%敏感,包括:;头孢他啶、头孢吡肟、环丙沙星、庆大霉素、阿米卡星和哌拉西林-他唑巴坦。2019年未发现耐美罗培南的铜绿假单胞菌分离株。2020年,其对抗生素头孢他啶和哌拉西林-他唑巴坦的敏感性为20.0%,对环丙沙星的敏感性为60.0%,对抗生素庆大霉素和阿米卡星的敏感性为100%。耐多药美罗培南铜绿假单胞菌在2018年对头孢他啶(15.4%)和阿米卡星(69.2%)抗生素仍然敏感,而在2019年仅对阿米卡星敏感(37.5%)。2020年,铜绿假单胞杆菌对抗生素头孢他啶和头孢吡肟(11.1%)、哌拉西林-他唑巴坦(22.2%),阿米卡星可作为耐多药美罗培南铜绿假单胞菌的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
8
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信